ArticleInternational journal of clinical oncology2025

Adverse events of hepatic function disorder in Japanese patients with radically unresectable or metastatic renal cell carcinoma treated with pembrolizumab plus axitinib: a post-marketing surveillance study.

Mototsugu Oya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.